KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 85 filers reported holding KALA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 7.30 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,000 | -25.0% | 12,270 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -77.8% | 12,270 | -3.7% | 0.00% | – |
| Q1 2022 | $18,000 | -10.0% | 12,745 | -19.1% | 0.00% | – |
| Q4 2021 | $20,000 | -45.9% | 15,745 | +10.5% | 0.00% | – |
| Q3 2021 | $37,000 | -35.1% | 14,245 | +32.3% | 0.00% | – |
| Q2 2021 | $57,000 | +216.7% | 10,770 | +310.3% | 0.00% | – |
| Q1 2021 | $18,000 | +50.0% | 2,625 | +64.1% | 0.00% | – |
| Q3 2020 | $12,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |